IONIS DGAT2Rx

Drug Profile

IONIS DGAT2Rx

Alternative Names: IONIS-DGAT2Rx; ISIS 484137; ISIS-DGAT2Rx

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 08 Nov 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in Hungary (SC), Poland (SC) (NCT03334214)
  • 08 Nov 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in Canada (Parenteral) (NCT03334214)
  • 08 Nov 2017 Phase-II clinical trials in Type-2 diabetes mellitus in Canada (SC) (NCT03334214)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top